home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Pharmexa reports progress in US breast cancer trial

 
  September, 14 2003 15:09
your information resource in human molecular genetics
 
     
12.09.2003 - In March 2003 Pharmexa submitted an application to start a clinical phase I trial with the company's HER-2 AutoVac(TM) Protein vaccine to the US health authorities. The application was among other things based on very promising preclinical results, where injections with HER-2 AutoVac(TM) Protein induced antibody levels comparable to therapeutic levels of the monoclonal antibody Herceptin. Herceptin is being marketed with great success for the treatment of metastatic HER-2 positive breast cancer by the international pharmaceutical companies Roche and Genentech.

The clinical trial, which takes place at two US breast cancer centres in Cleveland and Pittsburgh, includes 10 patients with breast cancer. The primary objective of the trial is to evaluate the safety of the HER-2 AutoVac(TM) Protein vaccine. In addition, the ability of the vaccine to activate a specific immune response against cancer cells expressing the HER-2 protein will be evaluated.

Recruitment of patients to the trial has now been completed according to schedule and all 10 patients have started treatment. Based on this, Pharmexa expects to be able to announce preliminary data from the trial before the end of the year.

WWW: http://www.pharmexa.com/


Message posted by: Frank S. Zollmann

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.